DE3872151D1 - Immobilisierung einer bioaktiven substanz an einer lipidzusammensetzung, enthaltend eine modofizierte lipidverbindung. - Google Patents

Immobilisierung einer bioaktiven substanz an einer lipidzusammensetzung, enthaltend eine modofizierte lipidverbindung.

Info

Publication number
DE3872151D1
DE3872151D1 DE8888308701T DE3872151T DE3872151D1 DE 3872151 D1 DE3872151 D1 DE 3872151D1 DE 8888308701 T DE8888308701 T DE 8888308701T DE 3872151 T DE3872151 T DE 3872151T DE 3872151 D1 DE3872151 D1 DE 3872151D1
Authority
DE
Germany
Prior art keywords
lipid
modofized
immobilization
composition containing
bioactive substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8888308701T
Other languages
English (en)
Other versions
DE3872151T2 (de
Inventor
C O Kabushiki Kaisha Ishimori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toshiba Corp
Original Assignee
Toshiba Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP23477787A external-priority patent/JPS6478163A/ja
Priority claimed from JP23778087A external-priority patent/JP2509636B2/ja
Priority claimed from JP6226488A external-priority patent/JPH0235362A/ja
Application filed by Toshiba Corp filed Critical Toshiba Corp
Application granted granted Critical
Publication of DE3872151D1 publication Critical patent/DE3872151D1/de
Publication of DE3872151T2 publication Critical patent/DE3872151T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/5432Liposomes or microcapsules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • C07F9/10Phosphatides, e.g. lecithin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Preparation (AREA)
DE8888308701T 1987-09-21 1988-09-20 Immobilisierung einer bioaktiven substanz an einer lipidzusammensetzung, enthaltend eine modofizierte lipidverbindung. Expired - Fee Related DE3872151T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP23477787A JPS6478163A (en) 1987-09-21 1987-09-21 Reagent for immunoassay
JP23778087A JP2509636B2 (ja) 1987-09-22 1987-09-22 生理活性物質固定化組成物
JP6226488A JPH0235362A (ja) 1988-03-16 1988-03-16 リポソーム上への生理活性物質の固定化方法

Publications (2)

Publication Number Publication Date
DE3872151D1 true DE3872151D1 (de) 1992-07-23
DE3872151T2 DE3872151T2 (de) 1993-03-18

Family

ID=27297786

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8888308701T Expired - Fee Related DE3872151T2 (de) 1987-09-21 1988-09-20 Immobilisierung einer bioaktiven substanz an einer lipidzusammensetzung, enthaltend eine modofizierte lipidverbindung.

Country Status (3)

Country Link
US (1) US5080833A (de)
EP (1) EP0312212B1 (de)
DE (1) DE3872151T2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5109118A (en) * 1989-07-06 1992-04-28 Yutaka Mizushima Modified biologically active proteins
EP0437092A1 (de) * 1989-12-25 1991-07-17 Kabushiki Kaisha Toshiba Gendiagnose
WO1992005773A1 (en) * 1990-10-09 1992-04-16 Vestar, Inc. Phospholipid analogue vesicle with a succinimidyl moiety
US5736371A (en) * 1991-06-04 1998-04-07 A Et S Biovecteurs Biodegradable particulate vector for transporting molecules having biological activity
CA2087397A1 (en) * 1992-01-22 1993-07-23 Kazuhisa Kubotsu Immunoassay and reagents used therefor
US5846516A (en) * 1992-06-03 1998-12-08 Alliance Pharmaceutial Corp. Perfluoroalkylated amphiphilic phosphorus compounds: preparation and biomedical applications
DK0699068T3 (da) * 1993-05-21 2002-03-11 Liposome Co Inc Reduktion af liposominducerede fysiologiske bivirkninger
JP2001208754A (ja) * 2000-01-26 2001-08-03 Kazunori Kataoka 生物学的な被検体を検出するための組成物
EP2776013B8 (de) 2011-11-08 2023-08-30 The Board of Trustees of the University of Arkansas Verfahren und zusammensetzungen zur röntgeninduzierten freisetzung ph-empfindlicher liposome

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3564099A (en) * 1967-05-29 1971-02-16 Monsanto Co Animal feed compositions and methods
US4218539A (en) * 1978-03-24 1980-08-19 Weltman Joel K Enzyme conjugates and method of preparation and use
US4480041A (en) * 1982-07-09 1984-10-30 Collaborative Research, Inc. Use of phosphotriester intermediates for preparation of functionalized liposomes
US4544545A (en) * 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPH06100601B2 (ja) * 1983-11-30 1994-12-12 株式会社東芝 免疫分析用試薬及びそれを用いた分析方法
JPS62163966A (ja) * 1986-01-16 1987-07-20 Toshiba Corp 補体価測定用試薬
JPS62214357A (ja) * 1986-03-17 1987-09-21 Toshiba Corp 免疫分析用試薬の製造方法

Also Published As

Publication number Publication date
EP0312212B1 (de) 1992-06-17
DE3872151T2 (de) 1993-03-18
EP0312212A1 (de) 1989-04-19
US5080833A (en) 1992-01-14

Similar Documents

Publication Publication Date Title
DE3876558D1 (de) Hyposensibilisierend wirksame substanz.
ES2015061B3 (es) Ingrediente antiespuma.
FI875391A0 (fi) Roekningsprodukt med foerbaettrat aerosol bildande substrat.
DE3869041D1 (de) Bremse.
DE69014498D1 (de) Hyposensibilisierende wirksame Substanz.
ES549299A0 (es) Procedimiento para la obtencion de medicamentos que contienen 1-heteroaril-4--aril-pirazolin-5-onas.
NO885263D0 (no) Klebemiddelsammensetning.
NO880809L (no) Antihyperkolesterolemiske tetrazolforbindelser.
NO862587L (no) Fremgangsmaate for fremstilling av en injiserbar opploesning inneholdende et antitumorantracyklinglykosid.
FI872434A0 (fi) Pesticidala kompositioner och foerfarande foer deras framstaellning.
NO870594L (no) Tinnholdige antigromalinger.
DE3872151D1 (de) Immobilisierung einer bioaktiven substanz an einer lipidzusammensetzung, enthaltend eine modofizierte lipidverbindung.
DE3763628D1 (de) Mehrfachstrahl-lasertron.
IT8620297A0 (it) Composti stabilizzanti eprocedimento per la loro preparazione.
IT1230068B (it) Procedimento per la preparazione di n sulfoniluree.
NO861307L (no) Fremgangsmaate for fremstilling av cellulosemasse.
DE3883747D1 (de) Gelatinzusammensetzung.
NO883339D0 (no) Fremgangsmaate for fremstilling av benzimidazol-2-yl-pyridiniumforbindelser.
NO864306L (no) Fremgangsmaate for fremstilling av 5-aryl-2,4-dialkyl-3h-1,2,4-triazol-3-thioner.
IT8820495A0 (it) Procedimento per la preparazione di cumene.
IT1233411B (it) Composizione insetticida.
ATE93512T1 (de) Oximino-aether-verbindungen.
DE3888114D1 (de) Klebstoff-Zusammensetzung.
DE3878192D1 (de) N-phenyltetrahydrophthalimidverbindungen.
NO161779C (no) Fremgangsmaate for fremstilling av et antiforkjoelsespreparat.

Legal Events

Date Code Title Description
8332 No legal effect for de
8170 Reinstatement of the former position
8370 Indication of lapse of patent is to be deleted
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee